Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that James Mutamba, PhD, has joined the company as Chief Business Officer. Dr. Mutamba has broad experience in business development, corporate strategy and company formation and growth, including his most recent role as Vice President of Business and Corporate Development at Pyxis Oncology (Nasdaq:PYXS) and previous roles at Longwood Fund and PureTech Health, where he co-founded and helped to build multiple biotech and life sciences companies. In his role at Arrakis, he will be responsible for leading corporate strategy, business development, investor relations and finance as Arrakis enters its next stage of growth, advancing its pipeline of wholly owned and partnered programs toward the clinic.This press release features multimedia. View the full release here: https://www.businesswire.com/n
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait [Seeking Alpha]Seeking Alpha
PYXS
Earnings
- 11/7/23 - Beat
PYXS
Sec Filings
- 4/4/24 - Form EFFECT
- 4/4/24 - Form 424B2
- 4/3/24 - Form SC
- PYXS's page on the SEC website